Heartseed raises 2 billion JPY in series D funding to accelerate development of iPSC-derived stem cell therapy for heart failure
TOKYO--(BUSINESS WIRE)--#biotech--Heartseed (Heartseed Inc.), a Tokyo-based biotechnology company developing iPSC-derived cardiomyocytes for heart failure (HF),…